Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy

Mizukami, Takuro; Takahashi, Masaki; Sunakawa, Yu; Yuki, Satoshi; Kagawa, Yutaka; Takashima, Atsuo; Katō, K.; Denda, Tadamichi; Yamamoto, Yoshiyuki; Shiozawa, Manabu; Oki, Eiji; Okamoto, Wataru; Yoshino, Takayuki; Nakajima, Takako Eguchi

doi:10.1007/s11523-022-00880-3

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCRUM-Japan GI-SCREEN has been utilized to accelerate clinical trials and for novel research related to cancer biology. The genomic landscape and clinical outcomes according to the primary site in mCRC have been extensively studied and reported [17]. The TP53 variant was more commonly observed in left-sided CRC, whereas the KRAS and BRAF variants were more prevalent in right-sided CC.…”

Section: Introductionmentioning

confidence: 99%

Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)

Kajiwara,

Nishina,

Yamashita

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

The treatment strategies and prognoses of patients with metastatic colorectal cancer (CRC) differ according to the sidedness of the primary tumor. TP53 gain-of-function (GOF) and non-GOF variants have been reported to be differentially associated with prognosis by sidedness. We aimed to evaluate the sidedness-dependent prognostic impact of gene alterations in metastatic CRC. Patients enrolled between April 2017 and March 2019 were included in this study. Those excluded were individuals whose tumor tissues were obtained after chemotherapy and those who were enrolled in the study more than six months after starting first-line chemotherapy. Finally, we assessed 531 patients who underwent complete gene sequencing. The study revealed a significant difference in overall survival between individuals with left-sided CRC (n = 355) and right-sided colon cancer (CC) (n = 176) when considering the TP53 non-GOF variant, KRAS wild-type, NOTCH1 wild-type, NOTCH1 covariant, NOTCH3 sole variant, and MYC amplification. Multivariate analysis on each side revealed that the TP53 GOF and KRAS variants were independent poor prognostic factors for left-sided CRC (p = 0.03 and p < 0.01, respectively), and the TP53 non-GOF variant, BRAF V600E, and MYC amplification for right-sided CC (p < 0.05, p < 0.01, and p = 0.02, respectively). The NOTCH3 sole variant was an independent and favorable prognostic factor for left-sided CRC (p < 0.01). The prognostic significance of gene alterations differed between left-sided CRC and right-sided CC.

show abstract

Section: Introductionmentioning

confidence: 99%